peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical AB Announces Increase in Number of Shares and Votes

30 Nov 2018, 08:00
Regulatory information
Lund, Sweden, November 30, 2018 - Hansa Medical AB (PR Newswire) (Nasdaq Stockholm:HMED) (“Hansa Medical” or the “Company”), a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s registered share capital, number of outstanding shares and votes have increased during the month of November 2018.

As previously announced, the board of directors of Hansa Medical resolved on a share issue of 1,776,765 ordinary shares, on November 13, 2018, by virtue of authorization by the extraordinary general meeting held on October 29, 2018.

As of today, the total number of registered and outstanding shares of Hansa Medical amounts to 40,681,654, of which 39,959,890 are ordinary shares and 721,764 are class C shares. As of today, the number of votes in Hansa Medical amounts to 40,032,066.4 and the registered share capital amounts to SEK 40,681,654.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00am CET on November 30, 2018.

For further information, please contact:

Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert 
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902

About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.